Final analysis of phase I study of ceritinib in pediatric patients with malignancies harboring activated anaplastic lymphoma kinase (ALK).

被引：1
|
作者：
Schulte, Johannes H.
Moreno, Lucas
Ziegler, David Simon
Marshall, Lynley V.
Zwaan, C. Michel
Irwin, Meredith
Casanova, Michela
Sabado, Constantino
Wulff, Beate
Stegert, Mario
Wang, Luojun
Hurtado, Felipe K.
Branle, Fabrice
Fischer, Matthias
Geoerger, Birgit
机构：
[1] Charite Berlin Campus Virchow Klinikum, Berlin, Germany
[2] Hosp Univ Nino Jesus, Madrid, Spain
[3] Sydney Childrens Hosp, Kids Canc Ctr, Randwick, NSW, Australia
[4] Royal Marsden Hosp, London, England
[5] Inst Canc Res, London, England
[6] Sophia Childrens Univ Hosp, Erasmus MC, Rotterdam, Netherlands
[7] Princess Maxima Ctr Pediat Oncol Utrecht, Rotterdam, Netherlands
[8] Hosp Sick Children, Toronto, ON, Canada
[9] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[10] Hosp Valle De Hebron, Barcelona, Spain
[11] Univ Childrens Hosp III Essen, Essen, Germany
[12] Novartis Pharma AG, Basel, Switzerland
[13] Novartis Pharmaceut, E Hanover, NJ USA
[14] Novartis Inst Biomed Res, Oncol Clin Pharmacol, E Hanover, NJ USA
[15] Novartis Pharmaceut AG, Basel, Switzerland
[16] Univ Childrens Hosp Cologne, Cologne, Germany
[17] Univ Paris Saclay, Gustave Roussy Canc Ctr, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10505
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase 1 study of ceritinib in pediatric patients with malignancies harboring activated anaplastic lymphoma kinase (ALK): Safety, pharmacokinetics and efficacy results from the fed population
    Fischer, M.
    Wulff, B.
    Baruchel, S.
    Berlanga, P.
    Trahair, T.
    Mechinaud, F.
    Schulte, J.
    Modak, S.
    Merks, J. H.
    Zwaan, C. M.
    Marshall, L. V.
    Casanova, M.
    Branle, F.
    Malet, I.
    Emeremni, A. C.
    Geoerger, B.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S49 - S50
  • [2] Phase I study of ceritinib in pediatric patients (Pts) with malignancies harboring a genetic alteration in ALK (ALK plus ): Safety, pharmacokinetic (PK), and efficacy results.
    Geoerger, Birgit
    Schulte, Johannes
    Zwaan, Christian M.
    Casanova, Michela
    Fischer, Matthias
    Moreno, Lucas
    Trahair, Toby
    Jimenez, Irene
    Kang, Hyoung Jin
    Pappo, Alberto S.
    Schafer, Eric
    Weiss, Brian D.
    Healy, Mary Ellen
    Li, Ke
    Lin, Tiffany
    Boral, Anthony
    Pearson, Andrew D. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Ceritinib in Anaplastic Lymphoma Kinase (ALK) plus NSCLC Patients Pretreated With Only Crizotinib: ASCEND-1 Subgroup Analysis
    Shaw, A.
    Kim, D.
    Solomon, B.
    Felip, E.
    Riely, G.
    Schuler, M.
    Tan, D.
    Chow, L.
    Camidge, D. R.
    Urban, P.
    Ortmann, C.
    Malet, I.
    Mehra, R.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1896 - S1897
  • [4] A phase I study of the anaplastic lymphoma kinase inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients with advanced solid tumors
    Fountzilas, Christos
    Adjei, Alex
    Opyrchal, Mateusz
    Evans, Rachel
    Ghasemi, Mohammad
    Attwood, Kristopher
    Groman, Adrienne
    Bshara, Wiam
    Goey, Andrew
    Wilton, John
    Ma, Wen Wee
    Iyer, Renuka
    INTERNATIONAL JOURNAL OF CANCER, 2021, 149 (12) : 2063 - 2074
  • [5] PHASE II STUDY WITH CRIZOTINIB IN PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE LYMPHOMA RELAPSED/REFRACTORY TO CHEMOTHERAPY
    Bossi, E.
    Brioschi, F. A.
    Steidl, C.
    Baretta, S.
    Cantu, S.
    Verga, L.
    Fontana, D.
    Sharma, G. G.
    Mologni, L.
    Mussolin, L.
    Piazza, R. G.
    Gambacorti-Passerini, C.
    HAEMATOLOGICA, 2019, 104 : 63 - 63
  • [6] Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy
    Bossi, Elisa
    Aroldi, Andrea
    Brioschi, Filippo A.
    Steidl, Carolina
    Baretta, Silvia
    Renso, Rossella
    Verga, Luisa
    Fontana, Diletta
    Sharma, Geeta G.
    Mologni, Luca
    Mussolin, Lara
    Piazza, Rocco
    Gambacorti-Passerini, Carlo
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (12) : E319 - E321
  • [7] Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer
    Landi, Lorenza
    Cappuzzo, Federico
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (02) : 203 - 214
  • [8] Phase I Study of Tq-B3101 in Pediatric Patients with Relapsed/Refractory Anaplastic Lymphoma Kinase Positive Anaplastic Large Cell Lymphoma
    Lu, Suying
    Huang, Junting
    Sun, Feifei
    Wang, Juan
    Zhu, Jia
    Zhen, Zijun
    Cai, Ruiqing
    Zhang, Yizhuo
    BLOOD, 2022, 140 : 6604 - 6605
  • [9] Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK plus ) NSCLC: Subgroup analysis of the ASCEND-1 trial
    Tan, Daniel Shao-Weng
    Shaw, Alice Tsang
    Mehra, Ranee
    Felip, Enriqueta
    Chow, Laura Quan Man
    Camidge, D. Ross
    Vansteenkiste, Johan F.
    Sharma, Sunil
    De Pas, Tommaso
    Riely, Gregory J.
    Solomon, Benjamin J.
    Wolf, Juergen
    Thomas, Michael
    Schuler, Martin H.
    Liu, Geoffrey
    Santoro, Armando
    Geraides, Margarida
    Boral, Anthony
    Yovine, Alejandro Javier
    Kim, Dong-Wan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment
    Camidge, D. Ross
    Kono, Scott A.
    Flacco, Antonella
    Tan, Aik-Choon
    Doebele, Robert C.
    Zhou, Qing
    Crino, Lucio
    Franklin, Wilbur A.
    Varella-Garcia, Marileila
    CLINICAL CANCER RESEARCH, 2010, 16 (22) : 5581 - 5590
12345